IP Verse

Methods Of Treating Bladder Cancer - EP2575803

The patent EP2575803 was granted to Abraxis Bioscience on Jul 26, 2017. The application was originally filed on May 20, 2011 under application number EP11790192A. The patent is currently recorded with a legal status of "Revoked".

EP2575803

ABRAXIS BIOSCIENCE
Application Number
EP11790192A
Filing Date
May 20, 2011
Status
Revoked
Dec 21, 2018
Publication Date
Jul 26, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKApr 24, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2005004002
DESCRIPTIONUS2006263434
DESCRIPTIONUS2007082838
DESCRIPTIONUS5916596
DESCRIPTIONUS6096331
DESCRIPTIONUS6506405
DESCRIPTIONUS6537579
DESCRIPTIONUS6749868
DESCRIPTIONWO2008137148
INTERNATIONAL-SEARCH-REPORTUS2008255035
INTERNATIONAL-SEARCH-REPORTWO2006089290
INTERNATIONAL-SEARCH-REPORTWO2008060651
INTERNATIONAL-SEARCH-REPORTWO2010068925
INTERNATIONAL-SEARCH-REPORTWO2011025838
SEARCHUS2007116774

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- "ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)", Abraxane@ SmPC Abraxis BioScience, Inc., (20070501), pages 1 - 26, XP055483947
OPPOSITION- Anonymous, "A Phase Two Trial of Neoadjuvant ABl-007, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder", ClinicalTrials.gov archive, (20081202), URL: https://clinicaltrials.gov/archive/NCT00585689/2008_12_02, XP055483929
OPPOSITION- "Antimetabolites", British National Formulary, London, RPS Publishing & BMJ Group, (20080901), vol. 56, pages 462-463,472 - 473, 477, XP055483937
OPPOSITION- "A Phase Two Trial of Neoadjuvant ABl-007, Carboplatin andGemcitabine in Patients With Locally Advanced Carcinoma of the Bladder", ClinicalTials.gov archive, (20080102), pages 1 - 3, URL: https://clinicaltrials.gov/archive/NCT00585689/2008_01_02, XP055483919
OPPOSITION- BARLOW L J et al., "Novel intravesical therapies for non-muscle- invasive bladder cancer refractory to BCG", UROLOGIC ONCOLOGY, NEW YORK, NY, US, vol. 28, no. 1, ISSN 1078-1439, (20100101), pages 108 - 111, (20091228), XP026820997
OPPOSITION- HUSSAIN et al., "Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer", J Clin Oncol, (20010501), vol. 19, no. 9, pages 2527 - 2533, XP055483916
OPPOSITION- SRIDHAR, S.S., "A phase II study of single agent abraxane as second-line therapy in pateients with advanced urothelial carcinoma", ASCO University J Clin Oncol, vol. 27, (20090421), pages 1 - 2, URL: http://meetinglibrary.asco.org/content/33661-65, (20131114), XP002716416
OPPOSITION- THOMAS E STINCHCOMBE et al., "Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane(R)) on three treatment schedules in patients with solid tumors", CANCER CHEMOTHERAPY AND PHARMACOLOGY, BERLIN, DE, (20070207), vol. 60, no. 5, ISSN 1432-0843, pages 759 - 766, XP019539690
OPPOSITION- WONG J et al., "Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects", ADVANCED DRUG DELIVERY REVIEWS, (20080522), vol. 60, no. 8, pages 939 - 954, XP022624681
OPPOSITION- KRATZ et al., "Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles", JOURNAL OF CONTROLLED RELEASE, AMSTERDAM, NL, vol. 132, no. 3, ISSN 0168-3659, (20081218), pages 171 - 183, (20081129), XP025714816
OPPOSITION- SMITH et al., "A Phase II Trial of Neoadjuvant nab-paclitaxel, Carboplatin, and Gemcitabine (ACaG) in Patients With Locally Advanced Carcinoma of the Bladder", Urology, (20130000), vol. 82, pages 111 - 117, XP055483925
OPPOSITION- HENNENFENT K. L. et al., "Novel formulations of taxanes: a review. Old wine in a new bottle?", Annals of Oncology, (20060000), vol. 17, pages 735 - 749, XP008065745
OPPOSITION- GREEN et al., "Abraxane@, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small- cell lung cancer", Annals of Oncology, (20060000), vol. 17, no. 8, pages 1263 - 1268, XP055394562
OPPOSITION- SONPAVDE GURU et al., "Treatment of metastatic urothelial cancer: opportunities for drug discovery and development", BJU INTERNATIONAL, (20081100), vol. 102, no. 9, ISSN 1464-4096, pages 1354 - 1360, XP002716418
OPPOSITION- DESAI N. et al., "Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel", Clin Cancer Res, (20060000), vol. 12, no. 4, pages 1317 - 1324, XP055272968
OPPOSITION- CHIEN AMY J et al., "A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies", CLINICAL CANCER RESEARCH, (20090900), vol. 15, no. 17, ISSN 1078-0432, pages 5569 - 5575, XP002716417
OPPOSITION- SONPAVDE et al., "Novel agents for advanced bladder cancer", Ther Adv Med Oncol, (20090000), vol. 1, pages 37 - 50, XP055483904
SEARCH- BARLOW L J ET AL, "Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG", UROLOGIC ONCOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 28, no. 1, ISSN 1078-1439, (20100101), pages 108 - 111, (20091228), XP026820997 [X] 1-5,13,15 * the whole document * [Y] 14
SEARCH- Sridhar, S.S., "A phase II study of single agent abraxane as second-line therapy in pateients with advanced urothelial carcinoma", J Clin Oncol, vol. 27, no. suppl, abstr e16058, (20090421), pages 1 - 2, ASCO University, URL: http://meetinglibrary.asco.org/content/33661-65, (20131114), XP002716416 [X] 1,3-5,13,15 * the whole document * [Y] 14
SEARCH- THOMAS E STINCHCOMBE ET AL, "Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane(R)) on three treatment schedules in patients with solid tumors", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, (20070207), vol. 60, no. 5, doi:10.1007/S00280-007-0423-X, ISSN 1432-0843, pages 759 - 766, XP019539690 [X] 1,3,13 * the whole document * [Y] 14
SEARCH- WONG J ET AL, "Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, vol. 60, no. 8, doi:10.1016/J.ADDR.2007.11.008, ISSN 0169-409X, (20080522), pages 939 - 954, (20080207), XP022624681 [X] 1 * the whole document * [Y] 6-12
SEARCH- KRATZ ET AL, "Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 132, no. 3, doi:10.1016/J.JCONREL.2008.05.010, ISSN 0168-3659, (20081218), pages 171 - 183, (20081129), XP025714816 [Y] 14 * page 174 - pages 180-181 *
SEARCH- SONPAVDE GURU ET AL, "Treatment of metastatic urothelial cancer: opportunities for drug discovery and development", BJU INTERNATIONAL, (200811), vol. 102, no. 9, Part B, ISSN 1464-4096, pages 1354 - 1360, XP002716418 [X] 1,3-5,13,15 * the whole document * [Y] 6-12,14
SEARCH- CHIEN AMY J ET AL, "A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies", CLINICAL CANCER RESEARCH, (200909), vol. 15, no. 17, ISSN 1078-0432, pages 5569 - 5575, XP002716417 [X] 1,3,5,13 * page 5570 * [Y] 6,8,14

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents